BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24246451)

  • 1. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation of p53 mutations with other oncogenic alterations in cancer.
    Girardini JE; Walerych D; Del Sal G
    Subcell Biochem; 2014; 85():41-70. PubMed ID: 25201188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
    Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
    [No Abstract]   [Full Text] [Related]  

  • 11. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutant p53 through the mevalonate pathway.
    Freed-Pastor W; Prives C
    Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of the transcription activation function to mutant p53 in human cancer cells.
    Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
    Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Stat3 in regulating p53 expression and function.
    Niu G; Wright KL; Ma Y; Wright GM; Huang M; Irby R; Briggs J; Karras J; Cress WD; Pardoll D; Jove R; Chen J; Yu H
    Mol Cell Biol; 2005 Sep; 25(17):7432-40. PubMed ID: 16107692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in p53 research: an interdisciplinary perspective.
    Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
    Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
    Pugacheva EN; Ivanov AV; Kravchenko JE; Kopnin BP; Levine AJ; Chumakov PM
    Oncogene; 2002 Jul; 21(30):4595-600. PubMed ID: 12096336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mutant p53 in cancer: a long road to precision therapy.
    Mantovani F; Walerych D; Sal GD
    FEBS J; 2017 Mar; 284(6):837-850. PubMed ID: 27808469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.